A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (NCT03900429)
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
🩺 Plain-English Summary (8th-Grade Level)
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (247 Sites)
Showing the first 25 of 247 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- East Valley Family Physicians — Chandler, Arizona
- The Institute for Liver Health - Chandler — Chandler, Arizona
- The Institute for Liver Health - Glendale — Glendale, Arizona
- Desert Clinical Research — Mesa, Arizona
- Adobe Gastroenterology — Tucson, Arizona
- The Institute for Liver Health - Tucson — Tucson, Arizona
- Arkansas Gastroenterology — North Little Rock, Arkansas
- Fresno Clinical Research Center — Fresno, California
- National Research Institute - Huntington Park — Huntington Park, California
- University of California San Diego — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
- National Research Institute - Los Angeles — Los Angeles, California
- Ruane Clinical Research — Los Angeles, California
- Stanford University School of Medicine — Palo Alto, California
- National Research Institute - Panorama City — Panorama City, California
- Alliance Clinical Research — Poway, California
- San Fernando Valley Health Institute — Van Nuys, California
- Colorado Springs Family Practice — Colorado Springs, Colorado
- South Denver Gastroenterology - Swedish Medical Center Office — Englewood, Colorado
- Excel Medical Clinical Trials — Boca Raton, Florida
- Covenant Metabolic Specialists - Fort Myers — Fort Myers, Florida
- University of Florida Hepatology Research at CTRB — Gainesville, Florida
- Nature Coast Clinical Research — Inverness, Florida
- Florida Research Institute — Lakewood Rch, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NASH - Nonalcoholic Steatohepatitis
- Statins for the Treatment of NASH — Rochester, Minnesota
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Birmingham, Alabama
- Estrogen Administration for the Treatment of NASH in Postmenopausal Women — Boston, Massachusetts
- Novel MRE Technique to Assess a Risk Factor for Liver Cancer — Stanford, California
- Hepatic Energy Fluxes in NASH and NAS Patients — Minneapolis, Minnesota
Explore by condition: All NASH - Nonalcoholic Steatohepatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.